{"id":"W4411343965","doi":"10.1002/hon.70094_220","title":"220 | HIGH EFFICACY OF BRIEF BRAF AND MEK COINHIBITION, ALONE AND COMBINED WITH ANTI‐CD20 IMMUNOTHERAPY, IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: A PHASE‐2 TRIAL","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Regeneron Pharmaceuticals; Celgene; Leukemia and Lymphoma Society of Canada; Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); CD20; Immunotherapy; Oncology; Leukemia; Cancer research; Internal medicine; Lymphoma; Cancer; Biology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001057354,0.001099161,0.001519173,0.0002803676,0.0003135608,0.00124529,0.0006295954,0.001238445,0.00469014],"category_scores_gemma":[0.00046166,0.0004704389,0.001131769,0.0002542934,0.0005410773,0.0007314811,0.0003180338,0.003013611,0.001630952],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005174988,"about_ca_system_score_gemma":0.0007276332,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004991826,"about_ca_topic_score_gemma":0.00103072,"domain_scores_codex":[0.9997557,0.00009093471,0.00001610907,0.00005057236,0.0000267535,0.00006002845],"domain_scores_gemma":[0.9997132,0.00005200058,0.00004158265,0.00003051227,0.0000185115,0.0001442049],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.776286,0.03977619,0.002258252,0.001592619,0.002275073,0.0002348976,0.0001649955,0.001414165,0.03148483,0.0004517298,0.008937966,0.1351232],"study_design_scores_gemma":[0.71141,0.2720298,0.005528949,0.00009045559,0.0007469543,0.0002896186,0.00003615938,0.001015618,0.003227802,0.0003362698,0.005250565,0.00003767475],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9847893,0.007836327,0.0005589859,0.0009228037,0.0005514242,0.001207976,0.0009034451,0.0002645518,0.002965345],"genre_scores_gemma":[0.988607,0.003179198,0.0006232024,0.001459716,0.0003998382,0.0009740255,0.001369104,0.00003726608,0.00335066],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00469014,"threshold_uncertainty_score":0.01569009,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01757900197584383,"score_gpt":0.3244681010151445,"score_spread":0.3068890990393007,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}